Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Production / Operations Routine +

LIGHT AI ACHIEVES ISO 13485 AND MDSAP CERTIFICATION, ADVANCING REGULATORY READINESS FOR HEALTH CANADA SUBMISSION OF QUICKSCAN(TM) SOFTWARE PLATFORM

Pre-revenue AI diagnostics developer advances regulatory clearance for smartphone-based Strep A detection amid persistent cash burn and dilution risk.

By The Northwire Desk — AI Analysis Jun 29, 2026 · 07:00 ALGO · 0.245 LIGHT AI INC.
Executive Summary
  • Light AI Inc. has obtained ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) certification from Intertek.
  • The certification validates the company's Quality Management System (QMS) for the design, development, and distribution of its AI/ML-powered SaMD platforms.
  • It specifically supports planned regulatory submissions to Health Canada for the QuickScan™ and QuickScan™ Strep A platforms.
  • The MDSAP certification satisfies regulatory requirements for Canada, the United States, and Australia.
  • Pre-FDA validation data cited in the release shows 96.57% accuracy in differentiating viral vs. bacterial pharyngitis and a 100% Negative Predictive Value for Strep A.
  • Management states the certification establishes the operational framework for ongoing regulatory, clinical, and commercialization activities, positioning the company to advance its Health Canada Medical Device License application.
Material Impact
  • The certification is a standard, necessary prerequisite for SaMD commercialization in regulated markets. It de-risks the Health Canada submission pathway but does not guarantee approval, reimbursement, or commercial adoption.
  • There is no immediate revenue impact, margin expansion, or cash flow improvement. The milestone is operational and regulatory in nature.
  • Given the company's recent announcement of an FDA pivotal trial initiation (June 4, 2026) and a New Zealand field study (June 15, 2026), this certification is an expected sequential step in the regulatory roadmap rather than an unexpected catalyst.
  • The market likely already priced in the regulatory timeline; therefore, the stock reaction is expected to be muted.
ALGO · Price
Company Overview
  • Light AI Inc. is a pre-revenue AI diagnostics company developing a smartphone-based Software as a Medical Device (SaMD) platform.
  • The core product, QuickScan™ Strep A, uses proprietary AI algorithms to analyze smartphone images for rapid detection of Group A Streptococcus (GAS) pharyngitis, eliminating the need for swabs or lab tests.
  • The platform targets community, school, and urgent-care settings, with a strategic vision to expand into eye, skin, and other infectious disease diagnostics.
  • The company is pursuing a dual-track regulatory strategy targeting both Health Canada and the U.S. FDA, while also exploring partnerships for deployment in lower- and middle-income countries.
Read the original news release →

More from LIGHT AI INC.

Jun 22, 2026 · 18:41

Pre-revenue AI diagnostics company closes dilutive financing to fund regulatory milestones amid going concern risks.

Financings Jun 19, 2026 · 18:00

Light AI Announces Closing of C$5,000,000 Secured Convertible Debenture Unit Financing

Financings Jun 15, 2026 · 18:25

Light AI pilots Strep A diagnostic in NZ as FDA pivotal trial launches, but pre-revenue status and going concern risk persist.

Production / Operations Jun 04, 2026 · 07:00

Light AI Advances FDA Pivotal Trial for Strep A AI Diagnostic Amid Cash Burn and Dilutive Financing

Regulatory May 21, 2026 · 07:15

Light AI’s C$5 Million Lifeline Comes With Dilutive Terms and Board Strings as Cash Burn Intensifies

Financings May 15, 2026 · 18:58

Pre-revenue diagnostics firm narrows losses but liquidity runway tightens ahead of commercial launch

Earnings